NO971900L - Mixtures and treatment of multiple sclerosis - Google Patents
Mixtures and treatment of multiple sclerosisInfo
- Publication number
- NO971900L NO971900L NO971900A NO971900A NO971900L NO 971900 L NO971900 L NO 971900L NO 971900 A NO971900 A NO 971900A NO 971900 A NO971900 A NO 971900A NO 971900 L NO971900 L NO 971900L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- multiple sclerosis
- treatment
- autoantigen
- myelin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000006386 Myelin Proteins Human genes 0.000 abstract 3
- 108010083674 Myelin Proteins Proteins 0.000 abstract 3
- 210000005012 myelin Anatomy 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Rehabilitation Therapy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Det beskrives isolerte peptider og kombinasjoner av peptider avledet fra myelin- autoantigener slik som MBP, MOG, PLP og MAG egnet for behandling av multippel sklerose, inkludert profylaktiske og terapeutiske blandinger og fremgangsmåter for forhindring eller behandling av multippel sklerose. Foretrukne blandinger som beskrives omfatter i det minste et isolert, renset peptid fritt for alle andre peptider eller kontaminanter, peptidet omfatter en aminosyresekvens, myelinautoantigenet som har T-celle aktivitet. En terapeutisk blanding som beskrives er istand til å nedregulere autoantigenet med spesifikk immunrespons til myelinautoantigenet i en populasjon av mennesker som lider av eller er mottagelig for multippel sklerose slik at sykdomssymptomene reduseres, elimineres eller reverseres og/eller starten eller progresjonen av sykdomssymptomene forhindres eller nedsettes. I tillegg kan blandingene og fremgangsmåtene som beskrives, når administrert i et langtkommet stadium av sykdommen, reversere pågående paralyse eller andre tegn på syk- dommen når administrert under den akutte fasen av sykdommen eller forhindre tilbakefall når adminstrert under remisjon.Isolated peptides and combinations of peptides derived from myelin autoantigens such as MBP, MOG, PLP and MAG are suitable for the treatment of multiple sclerosis, including prophylactic and therapeutic compositions and methods for the prevention or treatment of multiple sclerosis. Preferred compositions disclosed include at least one isolated, purified peptide free from all other peptides or contaminants, the peptide comprising an amino acid sequence, the myelin autoantigen having T cell activity. A therapeutic composition described is capable of down-regulating the autoantigen with specific immune response to the myelin autoantigen in a population of people suffering from or susceptible to multiple sclerosis so that the disease symptoms are reduced, eliminated or reversed and / or the onset or progression of the disease symptoms prevented or decreased. In addition, the compositions and methods described, when administered at an advanced stage of the disease, may reverse ongoing paralysis or other signs of the disease when administered during the acute phase of the disease or prevent relapse when administered during remission.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32822494A | 1994-10-25 | 1994-10-25 | |
| US40422895A | 1995-03-15 | 1995-03-15 | |
| PCT/US1995/013682 WO1996012737A2 (en) | 1994-10-25 | 1995-10-25 | Compositions and treatment for multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO971900D0 NO971900D0 (en) | 1997-04-24 |
| NO971900L true NO971900L (en) | 1997-06-25 |
Family
ID=26986277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO971900A NO971900L (en) | 1994-10-25 | 1997-04-24 | Mixtures and treatment of multiple sclerosis |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0787147A1 (en) |
| JP (1) | JPH10504039A (en) |
| AU (1) | AU4278296A (en) |
| BR (1) | BR9509438A (en) |
| CA (1) | CA2203629A1 (en) |
| CZ (1) | CZ122697A3 (en) |
| FI (1) | FI971750A7 (en) |
| HU (1) | HUT77047A (en) |
| IL (1) | IL115766A0 (en) |
| IS (1) | IS4466A (en) |
| NO (1) | NO971900L (en) |
| PL (1) | PL324091A1 (en) |
| SI (1) | SI9520118A (en) |
| SK (1) | SK51297A3 (en) |
| WO (1) | WO1996012737A2 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6252040B1 (en) * | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| US6156535A (en) | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
| CA2247009C (en) | 1996-03-21 | 2009-08-04 | Imperial College Of Science, Technology And Medicine | Cryptic peptides and method for their identification |
| CA2263730A1 (en) * | 1996-08-15 | 1998-02-19 | Agrivax Incorporated | Delivery of tolerogenic antigens via edible plants or plant-derived products |
| CA2494338C (en) * | 1997-04-04 | 2007-07-17 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| SE9703287D0 (en) * | 1997-09-11 | 1997-09-11 | Astra Ab | Peptides |
| CA2330826A1 (en) * | 1998-05-05 | 1999-11-11 | Corixa Corporation | Myelin basic protein peptides and uses thereof |
| US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| EP1080110A2 (en) * | 1998-05-19 | 2001-03-07 | Yeda Research And Development Co. Ltd. | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| EP1288226A1 (en) * | 2001-09-03 | 2003-03-05 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system |
| GB0202399D0 (en) | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| BR0308923A (en) | 2002-03-27 | 2005-01-04 | Aegera Therapeutics Inc | Antisense iap nucleobase oligomers and uses of these |
| DE10230381A1 (en) | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them |
| US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
| AU2007351813B2 (en) | 2006-10-31 | 2013-10-10 | East Carolina University | Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders |
| US8815794B2 (en) * | 2008-08-28 | 2014-08-26 | The Research Foundation For The State University Of New York | Treatment of amyloidoses using myelin basic protein and fragments thereof |
| EP2413958A4 (en) | 2009-03-31 | 2014-04-02 | Univ East Carolina | CYTOKINES AND NEUROANTIGENES FOR THE TREATMENT OF IMMUNE DISEASES |
| CN102781465A (en) | 2009-10-12 | 2012-11-14 | 生命生物实验室有限公司 | Composition for treatment of multiple sclerosis |
| RU2448685C2 (en) * | 2009-11-30 | 2012-04-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis |
| EP2688904B1 (en) * | 2011-03-21 | 2017-12-27 | Atlantic Cancer Research Institute | Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy |
| EP3094341B1 (en) | 2014-01-13 | 2019-10-02 | Berg LLC | Enolase 1 (eno1) compositions and uses thereof |
| ES2940607T3 (en) | 2015-12-03 | 2023-05-09 | Juno Therapeutics Inc | Modified Chimeric Receptors and Related Compositions and Methods |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0359783B2 (en) * | 1987-06-24 | 2002-04-17 | Autoimmune, Inc. | Treatment of autoimmune diseases by oral administration of autoantigens |
| US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| DK0506785T3 (en) * | 1989-12-20 | 2000-07-24 | Autoimmune Inc | Improved treatment of autoimmune diseases by aerosol administration of autoantigens |
| HUT61896A (en) * | 1990-03-02 | 1993-03-29 | Autoimmune Inc | Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases |
| IL97709A (en) * | 1990-03-30 | 2005-05-17 | Brigham & Womens Hospital | Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis |
| CA2053799C (en) * | 1991-10-22 | 2002-03-12 | Kenneth G. Warren | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
| WO1993009810A1 (en) * | 1991-11-19 | 1993-05-27 | Anergen, Inc. | Mhc subunit conjugates useful in ameliorating deleterious immune responses |
| JP3712260B2 (en) * | 1992-02-28 | 2005-11-02 | オートイミューン インク | Bystander suppression of autoimmune diseases |
| IL105153A (en) * | 1992-03-25 | 1999-12-22 | Immulogic Pharma Corp | Therapeutic compositions comprising peptides derived from human t cell reactive feline protein |
| ATE170874T1 (en) * | 1992-04-09 | 1998-09-15 | Autoimmune Inc | SUPPRESSION OF T-CELL PROLIFERATION USING PEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN |
| WO1993025661A1 (en) * | 1992-06-10 | 1993-12-23 | President And Fellows Of Harvard College | Heterogeneous proteolipid peptide 139-151-specific t cell clones |
| WO1994004121A1 (en) * | 1992-08-17 | 1994-03-03 | Autoimmune, Inc. | Bystander suppression of retroviral-associated neurological disease |
| NZ273813A (en) * | 1993-09-03 | 1998-05-27 | Immulogic Pharma Corp | Myelin oligodendrocyte glycoprotein autoantigen |
| WO1995007096A1 (en) * | 1993-09-06 | 1995-03-16 | La Trobe University | Treatment of autoimmune disease |
| CA2172512A1 (en) * | 1993-09-22 | 1995-03-30 | Lawrence Steinman | Interaction of t-cell receptors and antigen in autoimmune disease |
| CA2187345A1 (en) * | 1994-04-08 | 1995-10-19 | Howard L. Weiner | Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines |
| CA2185353A1 (en) * | 1994-04-08 | 1995-10-19 | David A. Hafler | Treatment of autoimmune disease using oral tolerization and/or type i interferon |
| SI9520059A (en) * | 1994-05-10 | 1997-08-31 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis. |
| DK0764273T3 (en) * | 1994-06-09 | 1999-06-23 | Tno | Alpha B crystallin for use in the diagnosis and therapy of autoimmune diseases, especially multiple sclerosis |
| US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
| ATE213499T1 (en) * | 1994-11-18 | 2002-03-15 | Neurocrine Biosciences Inc | PEPTIDE ANALOGUES OF HUMAN BASIC MYELIN PROTEIN WITH SUBSTITUTION AT POSITION 91 FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
-
1995
- 1995-10-25 CZ CZ971226A patent/CZ122697A3/en unknown
- 1995-10-25 SI SI9520118A patent/SI9520118A/en unknown
- 1995-10-25 HU HU9701843A patent/HUT77047A/en unknown
- 1995-10-25 JP JP8514109A patent/JPH10504039A/en active Pending
- 1995-10-25 IL IL11576695A patent/IL115766A0/en unknown
- 1995-10-25 AU AU42782/96A patent/AU4278296A/en not_active Abandoned
- 1995-10-25 EP EP95941330A patent/EP0787147A1/en not_active Withdrawn
- 1995-10-25 CA CA002203629A patent/CA2203629A1/en not_active Abandoned
- 1995-10-25 PL PL95324091A patent/PL324091A1/en unknown
- 1995-10-25 WO PCT/US1995/013682 patent/WO1996012737A2/en not_active Ceased
- 1995-10-25 BR BR9509438A patent/BR9509438A/en unknown
- 1995-10-25 SK SK512-97A patent/SK51297A3/en unknown
-
1997
- 1997-04-17 IS IS4466A patent/IS4466A/en unknown
- 1997-04-24 NO NO971900A patent/NO971900L/en unknown
- 1997-04-24 FI FI971750A patent/FI971750A7/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996012737A3 (en) | 1996-10-10 |
| FI971750A7 (en) | 1997-06-24 |
| AU4278296A (en) | 1996-05-15 |
| IS4466A (en) | 1997-04-17 |
| JPH10504039A (en) | 1998-04-14 |
| SK51297A3 (en) | 1998-03-04 |
| PL324091A1 (en) | 1998-05-11 |
| CZ122697A3 (en) | 1997-09-17 |
| BR9509438A (en) | 1997-12-23 |
| EP0787147A1 (en) | 1997-08-06 |
| SI9520118A (en) | 1998-08-31 |
| CA2203629A1 (en) | 1996-05-02 |
| FI971750A0 (en) | 1997-04-24 |
| HUT77047A (en) | 1998-03-02 |
| NO971900D0 (en) | 1997-04-24 |
| IL115766A0 (en) | 1996-01-19 |
| WO1996012737A2 (en) | 1996-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO971900L (en) | Mixtures and treatment of multiple sclerosis | |
| Neufeld et al. | Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes | |
| RU2007102698A (en) | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DISORDERS | |
| Polman et al. | Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat | |
| RU94046424A (en) | Method of separation of dna-ase forms, human dna-ase, pharmaceutical composition, method of dna-ase storage, treatment method | |
| US4818763A (en) | Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes | |
| KR0159046B1 (en) | Treatment of autoimmune diseases by aerosol administration of autoantigens | |
| Petrov et al. | Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity | |
| Kardys et al. | Experimental allergic encephalomyelitis in Lewis rats: immunoregulation of disease by a single amino acid substitution in the disease-inducing determinant. | |
| WO1995030435A3 (en) | Compositions and treatment for multiple sclerosis | |
| Yamada et al. | Bombesin-like immunoreactivity in human cerebrospinal fluid | |
| Silfvast | Prehospital resuscitation in Helsinki, Finland | |
| Hashim | Experimental allergic encephalomyelitis: activation of suppressor T lymphocytes by a modified sequence of the T effector determinant. | |
| JP4160505B2 (en) | Use of peptides containing post-translational type modifications in the concept of treatment of autoimmune diseases | |
| KR20080098488A (en) | HIV treatment | |
| Kaneko et al. | Purification and identification of endogenous anti-opioid substances from bovine brain | |
| Janković et al. | Enkephalinase-inhibitors modulate immune responses | |
| US20080207500A1 (en) | Medicament | |
| Kang et al. | Fulminating systemic capillary leak syndrome with lymphocytosis and hypogammaglobulinemia | |
| Geovese et al. | Giardiasis as a cause of hypokalemic myopathy in congenital immunodeficiency | |
| Jonung et al. | Indole amines and amino acids in various brain regions after infusion of branched chain amino acids into hepatectomized rats | |
| Oyaizu et al. | Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma | |
| Strian et al. | Anxiety Depression in Affective Disorders | |
| Schou et al. | Use of propranolol during lithium treatment: an enquiry and a suggestion | |
| US20250281568A1 (en) | Method for treating or preventing drug-induced liver injury with peptide composition |